Eyevensys
Paris
About Eyevensys
Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $52.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2021)
- Website: eyevensys.com
- Phone: +33 (0)1 84 79 10 60
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/eyevensys-271 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.